admin – Page 2697 – Vietnam News Gazette

November 15, 2022

VistaJet takes dining to new heights

VistaJet Private Dining

To new heights

The leading private aviation company redefines gastronomy in flight with expert scientific and artistic findings, signature seasonal menus and Michelin-starred partners

London, November 15, 2022: At a table at 45,000 feet — higher than Mount Everest — is probably the highest you will ever dine. This is the unique experience offered by VistaJet, the first and only global business aviation company, allowing passengers to embark on a curated voyage through the finest delicacies in the world — on board and at destination.

Even the greatest gourmand has to reset their senses when flying as the effects of altitude, lower humidity and increased noise and movement will have an effect, from metabolism to how we perceive different tastes. In particular, cabin air reduces the aroma that, together with taste, makes flavor — up to 80% of what people think is taste is, in fact, smell. Flying private, of course, does help to minimize the impact on the senses. At 45,000 feet, a VistaJet Global 7500 aircraft has an equivalent air pressure of only 4,500 feet and a controlled humidity level. But still, a difference can be noticeable.

Done well, food nourishes the heart and soul, body and mind. Why, then, is it so often the forgotten factor in the air — a necessity rather than a pleasure? Factors in flight are no reason to compromise.

VistaJet Private Dining

Preparing on board

“We have been on a journey to transform the private dining experience in the air — to make it something to savor”, says Diego Sabino, Vice President of Private Dining at VistaJet. “Simple things, big flavors and the best ingredients prepared and cooked to perfection will always travel well. We have explored the art and science of dining, so our Members can cherish time together on board, with the right taste, whatever the occasion.”

To ensure every passenger savors every bite, VistaJet’s expert eye to inspire the palate include:

Signature Seasonal Menus
VistaJet is focused on seasonality, health and wellbeing, continually evolving its menus for all — whether traveling for business, with family and friends, or celebrating a milestone — no matter where they are flying from.

VistaJet Private Dining

Welcome on board the VistaJet Global 7500

Perception of salt and sweetness reduces by 30%; while humidity in the home is typically around 45%, in an aircraft it can be 20% or less, desensitizing taste buds. That is why VistaJet works with more than 7,000 trusted suppliers around the world: the finest producers and purveyors to source the freshest and highest quality ingredients and dishes. Every dish is prepared for in-flight, high-altitude dining.

Renowned Partners
Even top chefs need to change the way they think about food that will be served on board a flight. Many of our award-winning partners have reformulated their iconic dishes and created exclusive meals to taste perfect in a VistaJet cabin.

Working with over 100 of the most sought-after private chefs and Michelin-starred restaurants for those special moments both in the sky and on the ground, our renowned Private World partners include a gateway to the most enlightening dishes — the revered Nobu Matsuhisa offering a new and exclusive dish onboard flights from the U.S.; Michelin-starred Alex Dilling from his eponymous restaurant at Hotel Café Royal in London; the inspired Nuhma Tuazon in New York; the delectable Tosca di Angelo at The Ritz Carlton in Hong Kong; the specialist Bon Soirée onboarding dishes from England; the legendary Zeffirino in Genoa, Italy; Chef Ivan Alvarez at the picturesque Ithaafushi — The Private Island, Maldives; the considered Origin Grill at the Shangri-La in Singapore; and a partnership with Taj Hotels around the world, including their Michelin-starred Chef Sriram of London’s Quilon, Varq at Taj Exotica Resort & Spa, The Palm Dubai, House of Ming at Taj Mahal Hotel New Delhi, Wasabi by Morimoto at Taj Mahal Palace Mumbai, and Thai Pavilion at the President, Mumbai.

The Little Book of Dining in the Sky
It is nearly impossible to recreate our favorite restaurant in the sky, and nor should we try — there are obvious limitations to space and cooking facilities, in addition to how food tastes, smells, looks and feels. But this is no reason to compromise.

The Little Book of Dining in the Sky explores the art and science behind eating well with VistaJet. Tasting notes, jet chef secrets, travel wellness, the jet kitchen and service suggestions for whomever you are dining with. The musings and expert advice are all aimed at helping you discover the pleasures of the table, at altitude.

The Process and Unparalleled Service
The story behind how food gets from farm to fork in flight is one of attention to detail across the entire supply chain. It is impossible to recreate the environment of a world-class kitchen in the sky, but we aim to come as close as possible.

As soon as your flight is booked, VistaJet’s Private Dining team will propose bespoke menus for you to choose from.
Sourcing specific ingredients can take a full day, while up to six hours might be needed to take food from the kitchen to the aircraft. Menus are finalised at least 24 hours before departure to ensure sourcing and preparation standards.
The private chef or restaurant starts creating the dishes. At this point any allergies, intolerances or other dietary needs will have been checked several times.
Hot dishes are freshly prepared by hand and par-cooked. Ingredients are packed into over-ready containers, and then blast-chilled to lock in taste, texture and freshness.
The meals are couriered to the departure airport in refrigerated vehicles and loaded onto the jet around 90 minutes before departure. VistaJet flies from 1,900 airports in 187 countries — about 96% of the world.
In the air, the VistaJet Cabin Host will finish cooking the food before it is expertly presented and served to passengers. All VistaJet Cabin Hosts are trained by the British Butler Institute, certified up to Level 2 in wine and spirits training and are food-safety qualified. They have also received expert plating tutorials from chefs specializing in different cuisines.

For more information on VistaJet and its private dining offerings, visit vistajet.com/privatedining.

ENDS

About VistaJet
VistaJet is the first and only global business aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world.
Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.
VistaJet is part of Vista — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.
More VistaJet information and news at vistajet.com

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet US Inc. is an Air Charter Broker that does not operate aircraft. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S. air carriers, including XOJET Aviation LLC.

Attachments

GlobeNewswire Distribution ID 1000756930

November 15, 2022

Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab

–The MAA was submitted in the EU for toripalimab seeking indications for the 1^st line treatment of NPC and the 1^st line treatment of ESCC

— The global commercialization plan for toripalimab has expanded from China to the US and now, the EU

SHANGHAI, China, Nov. 15, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (“EMA”) for toripalimab. The indications requested in the MAA are:

Toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”);
Toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”)

“From China to the US, and now the EU, the international commercialization of toripalimab is progressing steadily,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi/TopAlliance Biosciences, “This was made possible by the substantial efficacy observed in NPC and ESCC as well as the excellent safety profile of toripalimab exhibited across various cancers; these results are particularly impactful when it comes to currently unmet medical needs. For instance, in a randomized, confirmatory clinical study, toripalimab is the first immune checkpoint inhibitor (“ICI”) demonstrating a 13.2-month improvement in median progression-free survival and strong trend towards improved survival in patients with incurable NPC. Similarly, a randomized study has confirmed that toripalimab, in addition to taxane-based chemotherapy, significantly improves both survival and progression-free survival in patients with incurable ESCC. What is particularly notable is that efficacy was seen even patients with low PD-L1 tumor expression levels, for whom other ICI drugs do not appear efficacious. Going forward, we will continue to maintain close communication with the European regulatory agency and we look forward to making toripalimab available to patients in the EU as soon as possible.”

The MAA submission for NPC is based on the results from JUPITER-02 (an international randomized, placebo-controlled, double-blinded Phase III trial, NCT03581786) and POLARIS-02 (a multi-center, open label, pivotal Phase II clinical trial, NCT02915432). The JUPITER-02 results were first presented in June 2021 in a plenary session of the American Society of Clinical Oncology (“ASCO”) annual meeting (#LBA2) and subsequently published in detail as the cover article of the September 2021 issue of Nature Medicine. The POLARIS-02 results were published online in January 2021 in the Journal of Clinical Oncology.

In 2021, two indications for the treatment of NPC were approved by the National Medical Products Administration (“NMPA”) based on the results of POLARIS-02 and JUPITER-02, thereby making toripalimab the world’s first immune checkpoint inhibitor approved for the treatment of NPC. The FDA has accepted for review the resubmission of the Biologics License Application (“BLA”) for toripalimab for the treatment of NPC; the Prescription Drug User Fee Act (“PDUFA”) action date is set on December 23, 2022. If approved, toripalimab will be the first and only drug approved for the treatment of NPC in the U.S. In July 2022, toripalimab was designated as an orphan medicinal product by the European Commission (“EC”) for the treatment of NPC, and the designation will provide Junshi Biosciences with a number of incentives for research, development and marketing.

The MAA submission for ESCC is based on the results from JUPITER-06 (a randomized, placebo-controlled, double-blinded, multi-center Phase III trial, NCT03829969). The study results were first presented in a mini-oral session during the European Society for Medical Oncology (“ESMO”) Congress 2021, and later published in Cancer Cell with an editorial preview. In May 2022, the supplemental new drug application (“sNDA”) for toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC was approved by the NMPA in China. Additionally, US FDA has also granted an orphan drug designation to toripalimab for the treatment of patients with ESCC.

About Nasopharyngeal Carcinoma
NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common head and neck cancers in China. According to the World Health Organization, the number of newly diagnosed NPC cases in 2020 has exceeded 130,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with chemotherapy and radiotherapy. In the United States and Europe, there are presently no drugs approved for the treatment of NPC, for which recommendations for initial treatment (gemcitabine and cisplatin) are based on randomized trials conducted in China.

About Esophageal Cancer
Esophageal cancer is one of the most common malignant tumors in alimentary tract. According to data released by GLOBOCAN 2020, 604,100 new esophageal cancer cases and 544,076 deaths due to esophageal cancer occurred globally. The incidence and death rates of esophageal cancer ranked seventh and sixth among all domestic malignant tumors respectively. ESCC and esophageal adenocarcinoma are the two main histological subtypes of esophageal cancer. For patients with advanced ESCC, recently updated ESMO guidelines recommend a platinum-fluoropyrimidine doublet with a PD-1 blocking antibody for treatment of locally advanced or metastatic ESCC. Of note, the indications for those PD-1 inhibitors approved in Europe are restricted to a subset of patients with ESCC. Therefore, there is an urgent unmet need for new drugs and treatments to extend the survival of patients with ESCC, particularly those with low PD-1 tumor expression.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

unresectable or metastatic melanoma after failure of standard systemic therapy;
recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC;
in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (“NRDL”) (2021 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for melanoma and NPC.

In the United States, the FDA is reviewing the BLA resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has set a PDUFA action date for December 23, 2022. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (“SCLC”).

In the European Union, toripalimab was also designated as an orphan medicinal product by the European Commission for the treatment of NPC. In November 2022, a MAA was submitted to the EMA for: 1)toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8696726

November 14, 2022

International Conference Urges Support for Religious Freedom and Human Rights

“Religious freedom is a hallmark of an open society”

Washington, DC, Nov. 14, 2022 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE

International Conference Urges Support for Religious Freedom and Human Rights

“Religious freedom is a hallmark of an open society”

The greatest difference between open, free societies and authoritarian regimes is respect for human rights and religious freedom, speakers told the Conference of Hope for Universal Human Rights and Religious Freedom, sponsored by The Washington Times Foundation and Think Tank 2022.

The conference, held Nov. 12 in South Korea and livestreamed to millions of viewers globally, concluded with a call to action for people worldwide to sign a Declaration on the Universal Value of Religious Freedom. “We call upon all people throughout the world to stand firmly against all forms of intolerance, prejudice, slander, and hate toward believers of our world’s religions,” says the statement.

“When we speak of human rights, the most basic, fundamental right would be religious freedom,” said Dr. Yun Young Ho, Chairman of the Steering Committee for Think Tank 2022. This right is well-known, he said, noting that freedom of religion was included in Article 18 of the Universal Declaration of Human Rights, adopted in 1948 by the United Nations General Assembly.

At a time when many religious groups face persecution, intolerance, discrimination, and violence in many countries, this is “a critical moment in which we must unite, we face the truth, and we move forward courageously based on the principles expressed in the Declaration on the Universal Value of Religious Freedom,” said Conference of Hope co-host Thomas P. McDevitt, Chairman of The Washington Times and board member of The Washington Times Foundation.

Speakers pointed to persecution of religious groups including Muslim Uyghurs, Tibetan Buddhists, Jews, Christians, Muslims, Ahmadis, Bahais, Jehovah’s Witnesses, Yazidis, Falun Gong, and, more recently, the Family Federation of World Peace and Unification, formerly the Unification Church, in Japan.

The Chinese Communist Party is “at war with all faiths,” said Ambassador Sam Brownback, former US senator who served as Ambassador-at-Large for International Religious Freedom (2018-2021).

In contrast, “religious freedom is a hallmark of an open society in a democracy” and democracies “must stand for religious freedom for everybody, everywhere, all the time,” he said.

“Why is evil so influential in today’s world? Because it has many allies. Three siblings are the most spread and efficient: Indifference, ignorance and fear (when we don´t care, when we do not know, or when we are scared to say or do something),” said Hon. Jan Figel, First Special Envoy for the Promotion of Freedom of Religion, European Union (2016-2019). “To overcome these siblings, we must invest more into active engagement, lifelong education, and civil courage. Then a century of hope may come, and a culture of human dignity may prevail over extreme violence, aggressive wars and a century of genocides.”

Several speakers addressed the persecution of the Family Federation in Japan that has intensified since the tragic and senseless assassination of former Prime Minister Shinzo Abe. The Paris-based CAP Freedom of Conscience, a respected UN NGO, filed a formal complaint with the UN Human Rights Committee in Geneva, saying that Japan’s “national tragedy” has been turned “into a bizarre narrative that makes the alleged assassin into a victim.”

“Religious liberty has been defined by the Holy See as the most violated human right in the 21^st century,” said Mr. Massimo Introvigne, Founder and Managing Director, Center for Studies on New Religions in Italy. “The events in Japan prove that the use of the word ‘cult’ to discriminate against and persecute peaceful religious movements has now reached intolerable levels and should be stopped. Those who do not publicly reject and denounce the campaigns against ‘cults’ are not real friends of religious freedom.”

“After World War II, the Soviet Union was aggressively working to bring Japan into the Communist sphere of influence,” said Hon. Newt Gingrich, US House Speaker (1995-1999). Japanese leaders, including Mr. Abe’s grandfather Prime Minister Nobusuke Kishi, met with Rev. Sun Myung Moon during the Cold War, he said, and “a natural relationship formed between the victory-over-communism movement, Mr. Kishi and many members of the Diet, especially the Liberal Democratic Party.”

Today, “we are seeing that many in the [Japanese] media are trying to dissolve the movement in Japan without any legal due process,” Mr. Gingrich said.

“We are not surprised that so many current and former members of the Liberal Democratic Party and other parties in Japan understood that work with the Universal Peace Federation, co-founded by Dr. Hak Ja Han Moon, was so important and collaborated with it,” said Pastor Paula White-Cain, former advisor to US President Donald Trump and director of the White House Faith and Opportunity Initiative. She added, “it is good for Japan, good for the Republic of Korea and for America and good for peace in Northeast Asia and the world.”

Former BBC Correspondent Humphrey Hawksley, who spoke live from London, recalled how the Family Federation and other NGOs helped him lead a BBC crew into North Korea. “The work the church did in the 1990s helped bring about a peace deal that took the prospect of war off the table on the Korean Peninsula, and it has been doing similar work since,” he said.

Cardinal Kelvin Felix, Archbishop emeritus of Castries, Saint Lucia, recalled meeting Japanese volunteers with the Women’s Federation for World Peace in the island nation of Dominica. “For 26 years, they have been conducting art classes at our Teachers’ Training College and in many schools around the country,” while also holding programs to strengthen family unions,” he said.

The Family Federation has had 4,300 of its members in Japan kidnapped and held in forced confinement by highly paid professional “faith breakers” during the last 45 years, said Norishige Kondo, an attorney in Japan who has been serving as legal counsel to the Association of Victims of Kidnappings, Forced Confinement and Conversions. Kidnapped victims have also suffered sexual assault, violence, and threats, he said. In one case, a medical doctor—who had critically ill patients under his care—was held for more than a year by kidnappers. Another man, Toro Goto, was held for more than 12 years. “Mr. Goto was able to maintain his faith,” Mr. Kondo added, “but 70 to 80 percent of the victims of forced conversions and kidnappings lose their faith due to these inhuman and illegal detentions.”

“Religious freedom has long been called the first freedom, like the famed ‘canary in the mine,’ the violation of which warns us of impending danger elsewhere,” said Doug Bandow, Senior Fellow at Cato Institute, who specializes in foreign policy and civil liberty.

A group called Open Doors lists 50 of the top persecutors of Christians and other faiths, starting with Afghanistan’s Taliban and North Korea’s regime, said Mr. Bandow. “Governments which refuse to protect us as we seek God—or otherwise address the transcendent—are unlikely to protect us as we exercise our conscience in other ways,” he added, noting that eroding of religious freedom leads to denials of free speech, debate, and elections, and breeds terrible conflicts, including terrorism and genocide.

Prof. W. Cole Durham Jr., who directs the International Center for Law and Religion Studies at Brigham Young University’s J. Reuben Clark Law School, recalled how leaders and members of the Church of Jesus Christ of Latter-Day Saints (LDS) endured decades of persecution, brutal rejection, and bloodshed. Today, the LDS Church is a major denomination, and its members are widely accepted. “Standing up under persecution builds a kind of strength, which is its own reward,” he said. Moreover, surviving persecution leads to “an intensified appreciation of the practical importance of the freedom of religion” and “empathy for the suffering of others,” he said.

The Washington Times Foundation, founded in 1984 in Washington, D.C., hosts numerous programs, including its monthly webcast “The Washington Brief,” to gather expert commentary on issues relating to peace and security in the world. Think Tank 2022, a project of the Universal Peace Federation, regularly mobilizes its worldwide network to promote dialogue, reconciliation and peace on the Korean Peninsula.

The Washington Times Foundation and Think Tank 2022 plan to continue sponsoring the Conference of Hope programs to promote peace and security globally—and especially on the Korean Peninsula and the Pacific Rim.

Neeyamo Named as a Potential Leader in 2022 Fosway 9-Grid™ for Cloud HR

The Fosway 9-Grid for Cloud HR is a five-dimensional market analysis model that assists buyers in making informed choices about HR Technology providers in the European Cloud HR market.

LOS GATOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) — Neeyamo, a market leader in providing global payroll and global work solutions, has been named a Potential Leader in the 2022 Fosway 9-Grid for Cloud HR.

Fosway Group is Europe’s leading HR industry analyst focused on Next Gen HR, Talent, and Learning, and analyzing the realities of the market to provide insights on the future of work.

The Fosway 9-Grid for Cloud HR is a five-dimensional market analysis model that assists buyers in making informed choices about HR Technology providers in the European Cloud HR market. In addition, it helps evaluate current providers and stay up to date on the latest market developments.

The 9-Grid includes nine zones – Potential Leader, Strategic Challenger, Strategic Leader, Potential Challenger, Core Challenger, Core Leader, Potential Performer, Solid Performer, and Strong Performer. This year’s report includes 37 cloud HCM vendors based on potential, performance, presence, the total cost of ownership, and future trajectory.

Samuel Isaac, Senior Vice President, Strategy at Neeyamo, said, “Global HR technology market is slowly getting clouded with customers having to struggle between perception and reality. Neeyamo has been at the forefront of disrupting the global HR & payroll tech landscape, leveraging cutting-edge technology, global functional knowledge, and innovation. Our solution has a single native global engine at its core, making all the difference. We are proud to set the trend and demonstrate to the world that what was perceived impossible can be done. Amongst others, our positioning as a Potential Leader in cloud HR is a testament to our commitment to continuously innovate and execute strategies designed towards the future of work.”

“The financial well-being of employees is becoming a priority for HR teams as the cost of living crisis impacts organizations across all geographies,” said David Wilson, CEO, Fosway Group. “This has put the spotlight on payroll and the need for innovative payroll services at scale, something that Neeyamo continues to deliver as it consolidates its position as Potential Leader in the 2022 Fosway 9-Grid for Cloud HR.”

About Neeyamo

Neeyamo is a leading technology-enabled global payroll and EOR solutions provider for multinational and micro-multinational corporations worldwide. With an extensive team of professionals serving clients across 190+ countries, Neeyamo leverages its unique service-based model and functionality-rich, next-generation HR & payroll products portfolio to help organizations enable agile and scalable business. To know more, visit www.neeyamo.com.

About Fosway Group

Fosway Group is Europe’s #1 HR Industry Analyst. The Fosway 9-Grid provides a unique assessment of the principal learning and talent supply options available to organizations in EMEA. The analysis is based on extensive independent research and insights from the Fosway’s Corporate Research Network of over 250 customer organizations.

Visit the Fosway website at https://www.fosway.com/9-grid/ for more information on Fosway Group’s 9-Grid.

Contact Information:
Anika Panwar
Head of Corporate Communications
corporate.communications@neeyamo.com
+(91) 9176446649

This content was issued through the press release distribution service at Newswire.com.

GlobeNewswire Distribution ID 8695533

November 14, 2022

Government of St Kitts and Nevis does NOT accept cryptocurrency as a form of payment for its Citizenship by Investment programme

Basseterre, Nov. 14, 2022 (GLOBE NEWSWIRE) — The government of St Kitts and Nevis, along with the Citizenship by Investment Unit of the country, have refuted claims that investors interested in gaining citizenship to the country can pay using cryptocurrencies such as Bitcoin.

The St Kitts and Nevis citizenship by investment programme is the oldest in the world, having been established in 1984 – it has been providing investors from across the globe with one of the quickest, easiest, and most affordable routes to second citizenship.

Underpinned by a robust multi-layered due diligence process undertaken by international security firms from the USA and the UK, investors need to go through a formal application process consisting of eight main steps, which include:

Step 1: Pre-approval by a verified St Kitts and Nevis government agent and preparation of the application
Step 2: Submission of the citizenship application
Step 3: Application processing by the Citizenship by Investment Unit and internal and external due diligence checks
Step 4: Approval in principle letter issued
Step 5: Contribution to either the Sustainable Growth Fund or pre-approved real estate
Step 6: Bank clearance of source of funds
Step 7: Certificate of Registration issued
Step 8: Citizen can apply for a St Kitts and Nevis passport

Throughout the whole process, an investor will engage with an approved government agent who will facilitate the application and any payments will be made via registered banks using fiat money – a government-issued currency that is not backed by a commodity such as gold. An example would be the United States Dollar, Euro or Chinese Yuan.

Investors cannot make payments to a government-approved agent or the Citizenship by Investment Unit by using cryptocurrencies directly. These would need to be liquidated into fiat currency first and an applicant would need to provide a supporting affidavit regarding their source of funds as part of the application process.

St Kitts and Nevis has not yet passed any legislation regarding cryptocurrency. The country is participating in the Eastern Caribbean Central Bank (ECCB) pilot program, which aims to study the utilisation of cryptocurrency as a fiat currency.

The program’s purpose is to provide a safe and secure digital financial system by utilising the advantages of blockchain and is designed to exemplify the viability and functionality of the ECCB’s ability to issue Digital Eastern Caribbean Dollars.

The ECCB is the fiscal authority for the Eastern Caribbean Currency Union (ECCU).

Speaking at the Electronic Cash Conference 2022, which was held on November 12 2022, Prime Minister of St Kitts and Nevis, Dr Terrance Drew, expressed that while Bitcoin Cash – another form of cryptocurrency – is used as a method of tender by some businesses in the country, due diligence checks are presently being prioritised by his government ahead of any major decision concerning that cryptocurrency’s official use.

Prime Minister Drew stated that the financial safety and security of citizens is a matter of high priority, and the government, with the guidance of the ECCB, is prepared to explore the possibility of Bitcoin Cash being introduced as legal tender in the local financial space.

The Prime Minister explained that once all the crucial financial safeguards were in place, Bitcoin Cash could become accepted legal tender in St Kitts and Nevis by March 2023.

Benefits of gaining second citizenship to St Kitts and Nevis

Citizenship by Investment is a legal process to grant individuals – and, in some cases, their families – dual citizenship in exchange for a financial contribution to the country’s economy. The initiative permits countries to channel generated funds into developing healthcare, education, infrastructure, and more.

Being a citizen of St Kitts and Nevis offers investors a myriad of benefits including family reunification, global mobility, enhanced security, and increased economic opportunities.

St Kitts and Nevis offers award-winning and internationally acclaimed education institutions like veterinary and medical universities, attracting global-minded professionals. People from all over the world come to St Kitts and Nevis, over a million a year to be exact, because of its booming tourism sector.

In recent years, the nation has seen growing numbers of American visitors. Around 1,000 US citizens currently reside on the islands. Now, with more work-from-home policies than ever, many see the Caribbean as the perfect destination to get away from the bustle of big cities while continuing to be connected when business calls.

In addition to citizenship and global mobility, St Kitts and Nevis offers its citizens who choose to become tax residents a wide variety of insurance services in a tax-friendly environment. For example, the country guarantees financial privacy by not making any information about offshore business owners and top managers public.

Portfolio diversification is the first step in dispersing your investments so that your exposure is not limited to just one type of asset. An investment in property in St Kitts and Nevis would allow you to diversify your investment portfolio and potentially make a return upon selling that your share in real estate after the end of the minimum hold period.

This will also ensure that you retain a certain amount of your wealth outside of your home country. In uncertain political and economic climates, knowing that a portion of your portfolio is free from the grips of a potentially corrupt government can give you tremendous peace of mind.

PR St Kitts and Nevis
Government of St. Kitts and Nevis
mildred.thabane@csglobalpartners.com

GlobeNewswire Distribution ID 8696223

November 14, 2022

NASA’s Artemis Marks First-Ever 8K Immersive Live Broadcast

MeetMo and Felix & Paul Studios collaboration allows NASA Artemis 1 launch to be viewed worldwide in 8K live broadcast

MeetMo.io 360 Camera at NASA

LOS ANGELES, Nov. 14, 2022 (GLOBE NEWSWIRE) — As NASA begins taking the first step to return humanity to the moon, MeetMo.io is inviting the public to ride along, thanks to its innovative video streaming platform.

Beginning at 11:57 p.m. ET Nov. 15, MeetMo in collaboration with Felix & Paul Studios and FlightLine Films will simulcast in 8K & 4K 360° production to Meta Horizon Worlds Venues as well as the Space Explorers Facebook page. Full 360-degree streaming platforms will also be available via 5G in various locations and planetarium domes worldwide. Stay informed by visiting: https://explore.space

This event marks the first time any space launch has been available to view across the globe in ultra-high-resolution 8K Live broadcast. See link to former NASA astronauts Doug Hurley and Karen Nyberg: https://youtu.be/7ubwoAIxTV0

The Artemis program, a series of ongoing NASA space missions, aims to return humans to the moon for the first time in 50 years.

This unique immersive experience is made possible by Felix & Paul Studios and supported by technologies by MeetMo.io and FlightLine Films who will be providing up-close footage from multiple cameras strategically placed around Kennedy Space Center in Cape Canaveral, Florida. The collaboration of the three companies will allow the audience to have the most realistic and immersive viewing experience of this NASA moon launch. As the viewers are transported to the launch pad, they are able to feel the heat of the exhaust and hear the roar of the engines. They take a small step onto the launch pad as NASA begins taking a giant leap that will return mankind to the moon.

“Humanity’s deep space exploration came to an end with the final NASA Apollo mission in December of 1972,” said Michael Mansouri, MeetMo.io CEO. “Today, we are developing new content creation and distribution methods that can bring viewers experiences in ways not possible just a few short years ago.”

“Just as TV broadcasts of the ’70s ushered in a new era for home entertainment, today’s digital pioneers are paving new methods for hyper-realistic experiences,” Mansouri added. “We are honored to collaborate with our partners Felix & Paul Studios and FlightLine Films to capture and share this historic event with all of humanity as a never-before-seen immersive experience.”

Through proprietary encoding systems, MeetMo.io creates a real-time, cloud-based video collaboration space, delivering the highest quality streaming service available today. That system will power the experience for countless users as they view the NASA Artemis 1 launch in real-time.

“With our easy-to-use feature-rich MeetMo.io service, anyone working on any project can quickly capture and share key moments with decision-makers all over the world,” said Johan Romero, MeetMo.io chief technology officer. “In this case, it enables real-time assembly and the distribution of content across multiple platforms such as immersive domes or movie theaters, AR/VR devices, social media channels and live broadcasts.”

About MeetMo.io

MeetMo.io is a cloud-based streaming collaboration platform that connects people, devices and ideas in a hyper-secure place easily accessible worldwide. Our technology delivers high-quality video up to 8K resolution at the lowest latency for the most realistic experiences enabling a transformation in how we create and consume content.

For more information about MeetMo, visit MeetMo.io.

About Felix & Paul Studios

Felix & Paul Studios is an Emmy award-winning creator of immersive entertainment experiences, creating highly engaging, presence-based experiences for the next generation of technology-enabled devices and venues, including the touring life-scale immersive exhibit Space Explorers.

For more information about Felix and Paul Studios, visit felixandpaul.com.

About FlightLine Films

FlightLine Films has decades of experience in aerospace photography, range missile tracking, live broadcasting of sporting events. They were the first to gather 8.5 million concurrent viewers for a live-streaming event with the aerospace program Red Bull Stratos.

For more about FlightLine Films, visit flightlinefilms.com.

Contact Information:
Gianna Wolfe
VP
gianna@meetmo.io
323-642-1370

Kandao Obsidian Pro 12K 360° camera

Image 2: MeetMo.io NASA Artemis 360 cameras

Kandao Obsidian Pro 12K 360 camera used for the NASA Artemis Launch.

Image 3: Obsidian Pro 12K 360 Camera

Obsidian Pro 12K 360 Camera at NASA L-39 Launch Pad.

Image 4: Flightline Films JLAIR

This content was issued through the press release distribution service at Newswire.com.

Attachment

MeetMo.io 360 Camera at NASA

GlobeNewswire Distribution ID 8695520

November 14, 2022

Winners in the 19th Annual Stevie® Awards for Women in Business Announced

Women-Owned Businesses and Professionals Were Honored at an Awards Ceremony in Las Vegas

Winners named in 19th Stevie Awards for Women in Business program

Top female entrepreneurs, executives, and employees from around the world were named as Stevie Award winners at a ceremony in Las Vegas, NV U.S.A. on Friday, November 11.

FAIRFAX, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) — Shining a spotlight on women executives, entrepreneurs, and organizations run by women, winners in the 2022 Stevie® Awards for Women in Business were announced on Friday, November 11.

The Stevie Awards for Women in Business is an international competition produced by the creators of the prestigious International Business Awards® and American Business Awards®. The Stevie is widely considered to be the world’s premier business award.

With nominated working women and their guests in attendance, the awards were announced during a gala event at Caesars Palace in Las Vegas, Nevada. The 2022 competition attracted nominations from 27 nations.

The presentations were broadcast live via Livestream.

More than 1,500 nominations from organizations and individuals around the world were submitted to the awards this year for consideration in categories including Entrepreneur of the Year, Executive of the Year, Most Innovative Company of the Year, and Startup of the Year, among others. More than 200 business professionals working in seven specialized judging committees determined the Gold, Silver, and Bronze Stevie Award winners.

Grand Stevie Award trophies were presented to five organizations that submitted the best body of entries to the competition, in their own names or in the names of one or more clients. Winners were determined by the number of Gold, Silver, and Bronze Stevie Awards won in the competition. The Grand Stevie Award winners are:

The Audacious Agency, Coombabah, QLD, Australia (#1)
IBM, Armonk, NY, U.S.A. (#2)
Megaphone, Melbourne, Australia (#3)
Melissa Sones Consulting, New York, NY U.S.A. (#4)
Global Press Institute, Washington D.C., U.S.A. (#5)

The 2022 Gold, Silver, and Bronze Stevie Award winners reflect a diverse group of large and small organizations from around the globe. Notable Gold Stevie Award winners in this year’s competition include:

Sandrine Pons, Regional Vice President, Head of Solutions Sales & Innovation, SAP, Paris, France, for Women Helping Women – Business
Ann Kaplan, Las Vegas, NV U.S.A, for Woman of the Year – Accounting and Finance
Susan McLaughlin, Senior Innovative Media and Creative Operations Manager, Vanguard, Malvern, PA U.S.A, for Woman of the Year – Advertising, Marketing & Public Relations
Fatima Sultan Al-Kuwari, Group Chief Human Resources Officer, Ooredoo, Qatar, for Female Executive of the Year – Business Products –More Than 2,500 Employees
Shama Hyder, CEO and Founder, Zen Media, Plano, TX U.S.A., for Most Innovative Woman of the Year – Social Media
Stephanie Wernick Barker, President, Mondo, New York, NY U.S.A, for Female Thought Leader of the Year – Business Services
Gehad Hamdy, Founder, Speak Up, Giza, Egypt, for Social Change Maker of the Year – Gender
Michelle John, Founding Director, PEGS, Shrewsbury, Shropshire, United Kingdom, for Woman of the Year – Government or Non-Profit
Kelley Higney, Founder & CEO, Bug Bite Thing, Port Lucie, FL U.S.A, for Best Female Entrepreneur – Consumer Products –11 to 2,500 Employees
Allison Grafton, President and Founder, Rockwood Custom Homes, Calgary, Alberta, Canada, for Best Female Entrepreneur in Canada

Organizations that won more than one Gold Stevie Award include Anheuser-Busch InBev, Babylist, Brandless, But Bite Thing, Caroline Kennedy Group, Everise, Flock DC, Global Press Institute, Halkbank, Harman International, LickYourPhone Media, Luma Brighter Learning, Megaphone, Primrose Schools, Rockwood Custom Homes, Rubi Laboratories, Sidus Space, and The Tambellini Group.

HCLTech, the global technology company delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products, sponsored awards in four categories called HCLTech Women in Technology Awards. Among notable Stevie winners in those categories are:

Monica Williams, Senior Vice President – Digital Products and Content Distribution, NBCUniversal, for New Normal Digital Transformer
Karen Oerter, Director of Information Technology, Land O’Lakes, for New Normal Digital Transformer
Abby Knowles, Vice President Global Technology Solutions, Verizon, for Leading Through Uncertainty
Susan Doniz, CIO & SVP of Information Technology & Data Analytics, The Boeing Company, for Leading Through Uncertainty
Tia Ballard, Head of Cloud and Automation, Sempra, for Leadership in Next Gen Technology
Constance Metcalfe, Associate Vice President – Enterprise Infrastructure Transformation, Canadian Tire Corporation, for Excellence in Transforming Business

For a complete list of Stevie Award winners and more information, visit http://www.StevieAwards.com/Women.

The Stevie Awards staged the fifth edition of its Women|Future Conference virtually on November 8-10 in conjunction with the Stevie Awards for Women in Business. More than 250 women shared three days of programming highlighted by a keynote presentation by Rashmi Verma, head of D&I at Hugo Boss.

Entries for the 2023 (20th) edition of the awards will open in May. The 2023 awards ceremony will be held at the Marriott Marquis in New York, NY USA in November.

About the Stevie Awards

The Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Middle East & North Africa Stevie Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Contact:
Maggie Miller
Maggie@StevieAwards.com
+1 (703) 547-8389

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9aca97a3-922e-46f1-b2cd-9dcf4a1efcb8

GlobeNewswire Distribution ID 8695848